Search

everythinglearnresearchcommunity

for

Search:↓

Despite using finasteride, minoxidil, and RU58841, the user is experiencing slow hair loss, particularly at the hairline, and is considering additional treatments like microneedling and possibly switching to dutasteride. Concerns about medication side effects, such as reduced sperm count and performance anxiety, are also discussed.

Dutasteride works for most men, but some may experience worsening due to reasons like shedding, paranoia, non-androgenic alopecia, genetic variations, or smoking. Smoking can increase scalp DHT levels and damage follicles.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

A dermatologist advised stopping minoxidil and trying redensyl serum, while also starting finasteride. Concerns were raised about increased hair loss after stopping minoxidil.

My hairline, I am only 23. This conversation is about a user's experience with treatments for androgenic alopecia, including finasteride, dutasteride, RU, minoxidil, progesterone, melatonin, LLLT, oral minoxidil, and Pyrilutamide. They have tried many treatments over the course of two years without seeing much success, and they are considering getting a hair system as a last resort.

A user shared their 2-month progress on hair regrowth using oral minoxidil, oral finasteride, and topical minoxidil with pyrilutamide. They reported seeing tiny hairs growing and no side effects from finasteride so far.

The conversation discusses the effectiveness of RU58841 and pyrilutamide for hair loss treatment. It seeks personal success or failure stories and scientific data on these treatments.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions an update on Dr. Bloxham's Verteporfin treatment.

The user is seeking alternatives to Minoxidil due to heart issues and is considering microneedling with topical melatonin, copper peptides, resveratrol+fisetin, or stemoxydine, which reportedly have minimal side effects. They are asking for information on the effectiveness of these treatments.

OP uses 1mg finasteride, 2.5mg minoxidil, and 10mg biotin daily, along with a biotin, caffeine, and saw palmetto shampoo. OP noticed results after 5 months, with occasional heart palpitations from minoxidil.

Diffuse thinning is worse than a receding hairline as it affects the entire scalp, complicating styling and hair transplants. Treatments like finasteride, minoxidil, dutasteride, and RU58841 are mentioned, with some users noting improved hair density.

Salicylic Acid shampoo may hinder topical minoxidil but not oral minoxidil, which works through the liver. The user plans to continue using oral minoxidil and is concerned about the shampoo's effect on it.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A 22.5-year-old male is frustrated with doctors for not taking his diffuse thinning seriously. He has been using finasteride for 2.5 years, avoids topical minoxidil due to dandruff, and is hesitant about oral minoxidil due to weight and injury concerns.

The user is experiencing worsening hair loss despite using oral finasteride, oral minoxidil, microneedling, keto shampoo, and supplements for seven months. They are concerned about continued shedding and lack of regrowth, and are considering adding topical minoxidil to their routine.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The emotional impact of hair loss and the risks associated with common treatments such as finasteride, dutasteride, minoxidil, RU58841, and Fluridil. People discussed their personal experiences with these treatments, including potential side effects and lowered fertility. Hair transplants were also mentioned as a possible solution.

Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.

The user experienced significant hair improvement with minoxidil and finasteride but later faced shedding and diffused thinning after developing seborrheic dermatitis. They are seeking advice after trying treatments like ketoconazole, coal tar shampoos, fluconazole, and hydrocortisone cream.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

User shares 8-month progress on oral finasteride and minoxidil, noting initial success followed by a second shed. They seek advice on drug resistance and pill efficacy, with responses suggesting to push through the shed and consider the impact of cycling off minoxidil.

The user is managing hair loss with oral finasteride, recently switching to dutasteride, and topical minoxidil, but faces challenges due to seborrheic dermatitis. They seek advice on effective regrowth methods that don't worsen their condition, with suggestions including various shampoos like Vichy Dercos and ketoconazole.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses concerns that Minoxidil may cause skin aging, like collagen depletion and puffier faces. Some users suggest that a good skincare routine or collagen supplements might prevent these effects.

Microneedling may worsen hair loss due to potential scarring and inflammation, with some users suggesting caution and proper technique to avoid damage. Alternatives like Minoxidil, finasteride, and RU58841 are implied as safer options.

The user is experiencing severe side effects from finasteride, including sleep issues, depression, and gynecomastia, and is considering stopping the medication. They are exploring other treatments like RU58841 and dutasteride but are hesitant due to potential side effects.